Semaglutide slows but sustains
Your insurance company may deny coverage because your case may not meet their medical requirements for weight, BMI, A1c (a test for diabetes) or other weight-related health conditions
Scarcity Fear of missing out on a good deal or opportunity to prompt a quick response, limiting time for thorough research
Call (703) 637-3755 to speak with Leesburg, Virginia Weight Loss specialist, Lynese Lawson M.D
Stroke reduction In 2022, physician David Strain and colleagues reported an analysis of two clinical trials that measured the cardiovascular benefits of semaglutide in people with type 2 diabetes and high cardiovascular risk
The 48 week trial data represents the full evolution of these benefits, with most meaningful changes appearing after 12-24 weeks of consistent treatment